Hemostemix (HMTXF, $0.07) was a top loser over the last three months, falling -6 to $0.07 per share. A.I.dvisor analyzed 848 stocks in the Biotechnology Industry for the 3-month period ending April 17, 2025, and found that of them (2) exhibited an Uptrend while of them (7) demonstrated a Downtrend.